Diplomat Pharmacy (DPLO) Misses Q3 EPS by 3c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500 ends down as oil tops $100 per barrel
- Brent holds above $100 as tanker attacks dampen hopes for Hormuz traffic recovery
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- JPMorgan upgrades Meta on AI models and agents, sees ’meaningful headroom’
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- White House copper tariff plan stalls amid affordability concerns, sources say
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Diplomat Announces 3rd Quarter Financial Results
November 2, 2016 4:17 PM EDTFLINT, Mich., Nov. 2, 2016 /PRNewswire/ --Â Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended September 30, 2016. Â All comparisons, unless otherwise noted, are to the quarter ended September 30, 2015.
Third Quarter 2016 Highlights include:
Revenue of $1,181 million, an increase of 25% or $234 million 12% organic revenue growth Total prescriptions dispensed of 266,000, an increase of 9% Gross margin of 6.6% versus 8.0% Gross profit per prescription dispensed of $289, compared to $301... More